Please login to the form below

What everyone forgets about good organisational change in pharma

Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account.

When an organisation undergoes significant change, it can be make or break. On the one hand, if the company gets it wrong, it could end up with a toxic culture, high staff turnover rate and a loss of the company’s original mission – not to mention falling revenue.

On the other hand, when done well, an organisation could find itself better able to capture new opportunities, excite and galvanise employees and bring in new financial gains. If it fails to change at all, it could face a fate like that of Woolworths or Blockbuster – relegated to the history books.

In complex pharma markets there is often a greater need to be agile and reposition as the landscape transforms with the onset of new technology, diverse stakeholder relationships and competitor activities.

At some point, most companies will review the way they operate and find room for improvement. This could lead to small incremental changes or a full organisational transformation. Both require vision and sensitive execution, not to mention sparkling clarity in communications to stakeholders about why the change is taking place. However, these ‘softer’ steps are often overlooked, delaying the project and leading to higher costs.

Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account.

What’s the top challenge pharma companies face when it comes to organisational transformation?

DC: We are in the thick of embracing digital opportunities to reach customers, shifting from product focus to customer focus As a result, multichannel is shaking up pharma companies to the core. They must examine how well they really understand their customers, their mechanisms for building and deriving value from customer insight, and their strengths and weaknesses in non-sales-rep channels.

At BLH, we talk a lot about People, Process and Platforms as key facets of organisational change, and multichannel transformation truly touches all three. There is a need for holistic assessment and strategic design of any multichannel transformation endeavour.

Do pharma marketers need to evolve their skills sets to keep up with changes like multichannel marketing?

They do, but to really gain buy-in, it’s important to build the appropriate communication and motivation. Often this proves challenging for our clients. Training doesn’t just convey new material, it should also support learners in embedding the information into their daily working lives. Marketers are subject to a regular onslaught of training and development in different, but only have 1% of the working week to focus on these opportunities. They need to know the real value and benefit and to be able to learn in an efficient and effective manner.

Download the full article from Blue Latitude Health

6th December 2018

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Three strategies for managing loss of exclusivity successfully
Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
What does the future hold for Medical Affairs?
Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health